A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Exclusion Criteria

• •1. Stage IV (metastatic) breast cancer;
• •2. Bilateral breast cancer;
• •3. Patients who have received chemotherapy, endocrine therapy, targeted therapy, or radiotherapy for this disease;
• •4. Patients with a second primary malignancy, except for adequately treated skin cancer;
• •5. Major non-breast cancer-related surgical procedures within the past 4 weeks before enrollment, or patients have not fully recovered from such surgical procedures;
• •6. Severe heart disease or conditions that do not allow participation in the study, including but not limited to the following:
• •1. History of heart failure or systolic dysfunction (LVEF \< 50%);
• •2. High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate \> 100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-grade atrioventricular conduction blocks (i.e., Mobitz II second-degree atrioventricular block or third-degree atrioventricular block);
• •3. Angina pectoris requiring anti-anginal drug therapy;
• •4. Clinically significant valvular heart disease;
• •5. ECG showing a transmural myocardial infarction;
• •6. Uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg);
• •7. Due to severe and uncontrolled other medical conditions, the investigator considers chemotherapy to be contraindicated;
• •8. Known history of allergy to any component of the study drugs; patients with a history of immune deficiency diseases, including HIV positivity, or patients with other acquired or congenital immune deficiency diseases, or a history of organ transplantation.